Indaptus Therapeutics is trading 5.32% up now at $1.08 after reporting second-quarter 2026 results on August 13, 2026.
- Net loss narrowed to $1.8 million from $5.2 million; research and development expenses fell 83% to approximately $0.4 million.
- Cash and investments totaled $11.6 million, while management continued evaluating strategic alternatives following the Decoy20 clinical-program halt.
- The broader market is also modestly higher.